Risk Factors for Mortality in Critically Ill Patients with Coagulation Abnormalities:A Retrospective Cohort Study

Objective Coagulation abnormalities are common and prognostically significant in intensive care units(ICUs)and are associated with increased mortality.This study aimed to explore the association between the levels of coagulation markers and the risk of mortality among ICU patients with coagulation abnormalities.Methods This retrospective study investigated patients with coagulation abnormalities in the ICU between January 2021 and December 2022.The initial point for detecting hemostatic biomarkers due to clinical assessment of coagulation abnormalities was designated day 0.Patients were followed up for 28 days,and multivariate logistic regression analysis was utilized to identify risk factors for mortality.Results Of the 451 patients analyzed,115 died,and 336 were alive at the end of the 28-day period.Multivariate analysis revealed that elevated thrombin-antithrombin complex(TAT),tissue plasminogen activator inhibitor complex(tPAIC),prolonged prothrombin time,and thrombocytopenia were independent risk factors for mortality.For nonovert disseminated intravascular coagulation(DIC)patients,older age and thrombocytopenia were associated with increased risks of mortality,whereas elevated levels of plasminα2-plasmin inhibitor complex(PIC)were found to be independent predictors of survival.In patients with overt DIC,elevated levels of tPAIC were independently associated with increased risks of mortality.Nevertheless,thrombocytopenia was independently associated with increased risks of mortality in patients with pre-DIC.Conclusion Coagulation markers such as the TAT,tPAIC,PIC,and platelet count were significantly associated with mortality,underscoring the importance of maintaining a balance between coagulation and fibrinolysis.These findings highlight the potential for targeted therapeutic interventions based on specific coagulation markers to improve patient outcomes.

In silico evidence of Remdesivir action in blood coagulation cascade modulation in COVID-19 treatment

BACKGROUND Coronavirus disease 2019(COVID-19)has demonstrated several clinical manifestations which include not only respiratory system issues but also liver,kidney,and other organ injuries.One of these abnormalities is coagulopathies,including thrombosis and disseminated intravascular coagulation.Because of this,the administration of low molecular weight heparin is required for patients that need to be hospitalized.In addition,Remdesivir is an antiviral that was used against Middle East Acute Respiratory Syndrome,Ebola,Acute Respiratory Syndrome,and other diseases,showing satisfactory results on recovery.Besides,there is evidence suggesting that this medication can provide a better prognosis for patients with COVID-19.AIM To investigate in silico the interaction between Remdesivir and clotting factors,pursuing a possibility of using it as medicine.METHODS In this in silico study,the 3D structures of angiotensin-converting enzyme 2(ACE2),Factor I(fibrinogen),Factor II(prothrombin),Factor III(thromboplastin),Factor V(proaccelerin),Factor VII(proconvertin),Factor VIII(antihemophilic factor A),Factor IX(antihemophilic factor B),Factor X(Stuart-Prower factor),and Factor XI(precursor of thromboplastin(these structures are technically called receptors)were selected from the Protein Data Bank.The structures of the antivirals Remdesivir and Osetalmivir(these structures are called ligands)were selected from the PubChem database,while the structure of Atazanavir was selected from the ZINC database.The software AutoDock Tools(ADT)was used to prepare the receptors for molecular docking.Ions,peptides,water molecules,and other ones were removed from each ligand,and then,hydrogen atoms were added to the structures.The grid box was delimited and calculated using the same software ADT.A physiological environment with pH 7.4 is needed to make the ligands interact with the receptors,and still the software Marvin sketch®(ChemAxon®)was used to forecast the protonation state.To perform molecular docking,ADT and Vina software was connected.Using PyMol®software and Discovery studio®software from BIOVIA,it was possible to analyze the amino acid residues from receptors that were involved in the interactions with the ligands.Ligand tortions,atoms that participated in the interactions,and the type,strength,and duration of the interactions were also analyzed using those software.RESULTS Molecular docking analysis showed that Remdesivir and ACE2 had an affinity energy of-8.8 kcal/moL,forming a complex with eight hydrogen bonds involving seven atoms of Remdesivir and five amino acid residues of ACE2.Remdesivir and prothrombin had an interaction with six hydrogen bonds involving atoms of the drug and five amino acid residues of the clotting factor.Similar to that,Remdesivir and thromboplastin presented interactions via seven hydrogen bonds involving five atoms of the drug and four residues of the clotting factor.While Remdesivir and Factor V established a complex with seven hydrogen bonds between six antiviral atoms and six amino acid residues from the factor,and Factor VII connected with the drug by four hydrogen bonds,which involved three atoms of the drug and three residues of amino acids of the factor.The complex between Remdesivir and Factor IX formed an interaction via 11 hydrophilic bonds with seven atoms of the drug and seven residues of the clotting factor,plus one electrostatic bond and three hydrophobic interactions.Factor X and Remdesivir had an affinity energy of-9.6 kcal/moL,and the complex presented 10 hydrogen bonds and 14 different hydrophobic interactions which involved nine atoms of the drug and 16 amino acid residues of the clotting factor.The interaction between Remdesivir and Factor XI formed five hydrogen bonds involving five amino acid residues of the clotting factor and five of the antiviral atoms.CONCLUSION Because of the in silico significant affinity,Remdesivir possibly could act in the severe acute respiratory syndrome coronavirus 2 infection blockade by interacting with ACE2 and concomitantly act in the modulation of the coagulation cascade preventing the hypercoagulable state.

Change of Coagulation Factor Ⅷ and Antithrombin Ⅲ Activity in Bank-Stored Blood

Coagulation factor Ⅷ and antithrombin Ⅲ activity were detected in 15 health donors. It was found that antithrombin Ⅲ activity decreased obviously 12 h after blood drawing. It lost 56 % of the activity at the 3rd day, and 70 % of the activity at the 7th day. FⅧ:c showed no obvious change after 24 h, until the 3rd day. It lost 40 %-60 % of the activity after 36 h and was reduced to the 30 % of the original activity at the 5th day. Our results suggested that at the 3rd day coagulation factor Ⅷ of bank stored blood can be used to replenish antithrombin Ⅲ, while bank stored blood in one day can be used to replenish FⅧ.

ABO Blood Groups and Their Relationship with Coagulation Factor VIII in Healthy Adults

Background: ABO blood group distribution defers with racial and geographic variations. They are related to diseases like cardiovascular diseases, cerebral thromboembolism. ABO blood group system may influence coagulation factor VIII which may increase the future risk of thrombosis. Aim: To assess the relation of ABO blood group with coagulation factor VIII in healthy adults. Material and Methods: A prospective type of analytical cross-sectional study was conducted in the Department of Physiology, Dhaka Medical College, Dhaka from July 2019 to June 2020. After obtaining ethical clearance, a total of 190 healthy adults were selected from different areas of Dhaka city based on inclusion and exclusion criteria, with ages ranging from 18 - 45 years. The subjects were interviewed and detailed history regarding personal, family, medical and drug were taken. Prior to sample collection, informed written consent was taken from the participants. Individuals of blood group A were selected as group A, blood group B as group B, blood group AB as group AB and blood group O as group O. Coagulation factor VIII was measured in the Department of Hematology and BMT Unit, Dhaka Medical College Hospital, Dhaka. Blood grouping was done in the Department of Physiology, Dhaka Medical College, Dhaka. Statistical Analysis: For statistical analysis, ONE way ANOVA followed by Bonferroni test were considered using SPSS 25.0 version. Results: In this study, blood group B was most common (33.2%). Coagulation factor VIII was significantly higher (p < 0.001) in blood group A (105.76% ± 11.82%), B (112.00% ± 15.02%), AB (109.80% ± 11.93%) than blood group O (82.00% ± 12.86%). No significant difference was observed among A, B and AB blood groups regarding coagulation factor VIII. Conclusions: It can be concluded that blood group A, B, AB individuals may have more chance of thrombosis due to significantly higher coagulation factor VIII than blood group O individuals.

Effects of blood purification combined with Xuebijing on coagulation, immunity, inflammation and vascular factors in sepsis patients

Objective:To investigate the effects of blood purification combined with Xuebijing on coagulation, immunity, inflammation and vascular factors in sepsis patients.Methods: 82 sepsis patients admitted to the Xuzhou Municipal Hospital Affiliated to Xuzhou Medical University from January 2017 to January 2019 were selected as the research objects. According to the random drawing method, 41 cases in the control group and 41 cases in the observation group were divided into two groups. The control group was treated with routine western medicine, including antibiotic therapy, blood sugar control, respiratory support and nutritional support. The observation group was treated with continuous blood purification combined with Xuebijing on the basis of the control group. The changes of coagulation index, immune factor, inflammatory reaction and vascular factor levels were observed before and after treatment in two groups.Results:After treatment, the levels of activated partial thromboplastin time (APTT), prothrombin time (PT), D-Dimer (DD), CD8+, procalcitonin (PCT), Tumor Necrosis Factor-α (TNF-α), high mobility group box-B1 (HMGB1) and soluble fms-like tyrosine kinase,(sFLT)in the two groups were significantly lower than those before treatment, while the levels of CD4+, CD4+/CD8+, and vascular endothelial growth factor (VEGF) were significantly higher than those before treatment;and the levels of APTT, PT, DD, CD8+, PCT, TNF-a, HMGB1 and sFLT in the observation group after treatment were significantly lower than those in the control group, the levels of CD4+, CD4+/CD8+, and VEGF in the observation group after treatment were significantly higher than those in the control group, there was a significant difference in each indexes between the different groups after treatment. Conclusions:Continuous blood purification combined with Xuebijing therapy can effectively improve the coagulation function of sepsis patients, enhance the immune mechanism of patients, reduce inflammation and protect vascular endothelial function. It has clinical popularization significance.

Effect of Dan seven soft capsule adjuvant therapy on serum inflammatory factors, coagulation function and blood rheology indexes in patients with acute hemorrhagic cerebrovascular disease

Objective: To investigate the effect of Dan seven soft capsule on the treatment of acute hemorrhagic cerebrovascular disease and the influence of serum inflammatory factors, coagulation function and blood rheology indexes. Methods: A total of 112 cases of patients with acute hemorrhagic cerebrovascular disease, according to the random data table were divided into the control group (n=57) and observation group (n=55), the patients in the control group received routine treatment combined with edaravone, on the basis of the treatment of the control group, the observation group was treated with Dan seven soft capsule. The serum levels of inflammatory factors, coagulation function and blood rheology indexes were compared between the two groups before and after treatment. Results: Before treatment, there were no significant difference in the inflammatory factors (hs-CRP, TNF-α and IL-6), blood coagulation function (FIB, PT and APTT) and hemorheology (high cut whole blood viscosity, low cut whole blood viscosity and plasma viscosity) levels between the control group and observation group. Compared with the levels of the same group before treatment, two groups of hs-CRP, TNF-α, IL-6, FIB, high cut whole blood viscosity, low cut whole blood viscosity and plasma viscosity level after treatment were significantly decreased, and levels in the observation group were significantly lower than those in the control group;Compared with the group before treatment, the levels of PT and APTT in the two groups were significantly increased, and the observation group was significantly higher than the control group. Conclusion: Dan seven soft capsule in the treatment of acute hemorrhagic cerebrovascular disease can effectively reduce the level of serum inflammatory factors, improve coagulation function and blood rheology index, it has an important clinical value.

Preparation and Structure of a New Coagulation Factor XI Catalytic Domain for Drug Discovery

Human blood coagulation factor XI （FXI） is a key enzyme in the amplification phase of blood coagulation cascade, and is recognized as an important target for anti-coagulant development in recent years. We designed a new mutant form of FXIa catalytic domain rhFXI370-607 （N73Q-N113Q-C123S）, and report here the facile preparation, protein crystallization, and crystal structure of this protein. We highlight a few unique structural features of FXIa after comparison with the trypsin family serine proteases at sequence and structural levels. This work provides a foundation to develop new small molecular FXIa inhibitors with increased potency and specificity.

Effects of low molecular weight heparin on the function of blood coagulation and serum levels of TNF-α, CK-MB, CRP of patients with acute exacerbations of chronic obstructive pulmonary diseases and respiratory failur

Objective:To study the effects of low molecular weight heparin on the function of blood coagulation and serum levels of tumor necrosis factor-α(TNF-α), creatine kinase isoenzyme (CK-MB), C-reactive protein (CRP) of patients with acute exacerbations of chronic obstructive pulmonary diseases and respiratory failure.Methods:A total of 80 patients with acute exacerbations of chronic obstructive pulmonary diseases and respiratory failure in our hospital from June 2014 to October 2016 were enrolled in this study. The subjects were divided into the control group (n=40) and the treatment group (n=40) randomly. The control group were treated with conventional treatment, the treatment group were treated with the conventional treatment combined with low molecular weight heparin. The two groups were treated for 7 d. The D-dimer (D-D), fibrinogen (FBG), pro thrombin time (PT), thrombin time (TT), TNF-α, CK-MB and CRP of the two groups before and after treatment were compared.Results:There were no significantly differences of the blood levels of D-D, FBG, PT and TT of the two groups before treatment. After treatment, the blood levels of D-D and FBG of the two groups were significantly lower than before treatment, and that of the treatment group were significantly lower than the control group, the PT and TT of the two groups were significantly higher than before treatment, and that of the treatment group were significantly higher than the control group. There were no significantly differences of the serum levels of the TNF-α, CK-MB and CRP of the two groups before treatment. After treatment, the serum levels of the TNF-α, CK-MB and CRP of the two groups were significantly lower than before treatment, and that of the treatment group were significantly lower than the control group.Conclusion:Low molecular weight heparin can significantly reduce the inflammatory factors of the patients with acute exacerbations of chronic obstructive pulmonary diseases and respiratory failure, can alleviath the patients conditions and reduce the myocardial damage.

回收式自体输血在高出血风险产妇剖宫产术中的应用研究

目的探究回收式自体输血在高出血风险产妇剖宫产术中的应用效果。方法选取行剖宫产手术产妇100例,术前被诊断为具有高危出血风险,包括凶险性前置胎盘、胎盘植入、胎盘早剥、先兆子宫破裂以及疤痕子宫。依据输血方式不同,自体输血50例为观察组,异体输血50例为对照组。比较2组患者临床指标、血常规、凝血功能、炎症因子及术后不良反应。结果观察组术中失血量、术中输血量、血费、总费用、手术时间及住院时间少于或短于对照组,差异有统计学意义(P<0.05)。开始输血即刻(T_(1))时,2组产妇血常规指标比较差异均无统计学意义(P>0.05);输血结束(T_(2))及术后24 h(T_(3))时,2组红细胞压积(Hct)比较差异无统计学意义(P>0.05),观察组血红蛋白(Hb)、血小板(Plt)均高于对照组,差异有统计学意义(P<0.05)。T_(1)时,2组产妇凝血功能指标比较差异均无统计学意义(P>0.05);T_(2)、T_(3)时,2组D-二聚体(D-D)比较差异无统计学意义(P>0.05),观察组凝血酶原时间(PT)、凝血酶时间(TT)、活化部分凝血活酶时间(APTT)均短于对照组,纤维蛋白原(Fib)高于对照组,差异有统计学意义(P<0.05)。输血后48 h,观察组血清降钙素原(PCT)、白细胞介素-6(IL-6)均低于对照组,差异有统计学意义(P<0.05);观察组过敏反应、感染及低血压发生人数均低于对照组,但2组产妇总不良反应发生率比较差异无统计学意义(P>0.05)。结论回收式自体输血在高出血风险产妇剖宫产术中的临床应用效果显著。

常规出凝血检验自动审核规则的建立与验证

目的:建立常规出凝血检验项目结果自动审核规则,为临床实验室提高检验结果审核质量和效率提供参考。方法:收集2020年1-3月期间解放军总医院第一医学中心等8家医院检验科的24510份枸橼酸钠抗凝常规出凝血检测标本,根据随机抽样法将其分为规则建立组和规则验证组,规则建立组血标本6670份,其中差值检查2056份;规则验证组血标本17840份,其中差值检查3210份。使用StagoSTARMax全自动血凝分析仪及配套试剂检测凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)、纤维蛋白原(Fib)、凝血酶时间(TT)、D-二聚体(DD)和(或)抗凝血酶(AT)活性。以人工审核结果为标准,计算两组自动审核与人工假阴性率(无效审核)、假阳性率(无效拦截)、通过率、阳性符合率、阴性符合率、审核一致率和标本周转时间(TAT)。结果:建立的自动审核规则及规则应用流程,涉及室内质量控制、报警信息、自动审核范围、危急值和差值检查。规则建立组单个项目通过率为82.6%~92.4%,总体通过率为73.8%,自动审核与人工审核结果一致率为98.2%,阳性符合率和阴性符合率分别为24.4%和73.8%。规则验证组单个项目通过率为86.4%~91.5%,总体审核通过率为71.5%。模拟应用自动审核规则,8家医院中两家医院单位的平均TAT分别缩短1.5 h和2.1 h。结论:应用常规出凝血自动审核规则能够使人工审核工作量减少,明显缩短TAT,提高实验室工作效率。

温阳活血汤联合艾灸治疗寒凝血瘀型痛经临床研究

目的:探讨温阳活血汤联合艾灸治疗寒凝血瘀型痛经临床疗效。方法:选取原发性寒凝血瘀型痛经患者60例,将其随机分为两组,其中对照组单纯接受艾灸腰阳关治疗,观察组则接受艾灸腰阳关联合温阳活血汤治疗。观察两组治疗后临床疗效,同时进行痛经症状评分,在干预前、干预3个月经周期后采用VAS评分量表评估两组疼痛程度。另取血清以酶联免疫法检测白细胞介素-8(IL-8)、超敏C反应蛋白(hs-CRP)和肿瘤坏死因子-α(TNF-α)水平及前列腺素E2(PGE2)、神经生长因子(NGF)和前列腺素F2α(PGF2α)水平。结果:对照组和观察组总有效率分别为76.67%和93.33%,观察组明显高于对照组(P<0.05)。治疗后3个月,两组的痛经相关中医症状评分均显著低于治疗前,且观察组的症状评分均显著降低(均P<0.05);两组的疼痛视觉模拟评分(VAS)评分和COX痛经症状量表(CMSS)评分均降低,且与对照组相比,观察组的VAS评分和CMSS评分更低(均P<0.05)。治疗后,两组IL-8、hs-CRP、TNF-α、PGE2、NGF和PGF2α水平均较治疗前显著降低,与对照组比较,观察组水平降低更明显(均P<0.05)。观察组和对照组的不良反应发生率分别为6.67%和10.00%(P>0.05)。结论:温阳活血汤联合艾灸可降低IL-8、hs-CRP、TNF-α、PGE2、NGF和PGF2α水平,改善患者痛经症状。

降脂膏联合瑞舒伐他汀钙片治疗颈动脉易损斑块痰瘀互结证

目的探讨降脂膏联合瑞舒伐他汀钙片治疗颈动脉易损斑块痰瘀互结证临床疗效。方法按照随机数字表法将120例颈动脉易损斑块痰瘀互结证患者分成对照组与观察组,各60例。对照组采用瑞舒伐他汀钙片治疗,观察组在对照组基础上联合降脂膏治疗。观察2组治疗前后眩晕、头痛、耳鸣、肢体疼痛或麻木、胸胀中医证候积分、颈动脉超声相关指标IMT值、颈动脉斑块面积、颈总动脉收缩期Vmax、舒张期Vmin、颈总动脉RI、血清学指标肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)、hs-CRP、血脂水平、凝血指标凝血酶原时间(PT)、D-二聚体、凝血酶原国际标准化比(INR)水平变化,比较2组治疗总有效率及安全性。结果观察组治疗后各项中医证候积分、IMT值、颈动脉斑块面积、颈总动脉RI、TNF-α、IL-6、hs-CRP、TG、TC、LDL-C、PT、D-二聚体、INR水平均低于对照组(P<0.05),颈总动脉收缩期Vmax、舒张期Vmin、HDL-C水平及治疗总有效率均高于对照组(P<0.05);2组治疗期间均无明显不良反应发生。结论降脂膏联合瑞舒伐他汀钙片能够显著缓解颈动脉易损斑块痰瘀互结证症状,降低血脂指标、血液高凝态、炎症因子,改善颈动脉血流速度。

重视非肝硬化内脏静脉血栓的病因筛查

非肝硬化内脏静脉血栓(NC-SVT)主要包括门静脉血栓、肠系膜上静脉血栓、脾静脉血栓和肝静脉血栓(布加综合征),其患病率随着相关基础疾病发病率升高而呈现上升趋势。由于NC-SVT严重的危害性,临床医生对其诊断意识和诊断能力也明显提高。但在治疗上往往只重视抗凝、介入等针对血栓的处理,而忽视对导致SVT的危险因素或基础疾病的筛查,一定程度上影响部分患者的血栓治疗效果,也将延误对基础疾病的诊断和治疗。本文简要介绍了与NC-SVT发生相关的获得性、遗传性及系统性、局部性基础疾病。

补肾通脉方对急性ST段抬高型心肌梗死PCI术后凝血-纤溶系统及血脂的影响

目的:观察补肾通脉方对急性ST段抬高型心肌梗死经皮冠状动脉介入术(PCI)术后凝血-纤溶系统及血脂的影响。方法:选取2017年3月—2020年3月南京中医药大学附属徐州中医院收治的92例急性ST段抬高型心肌梗死患者,按照随机分组的方法,将其分为对照组和治疗组,各46例。入组患者均给予标准化内科治疗,治疗组在标准治疗的基础上加用补肾通脉方。观察两组治疗前后纤维蛋白原(FIB)、抗凝血酶Ⅲ(AT-Ⅲ)、组织型纤溶酶原激活物(t-PA)、纤溶酶原活化物抑制剂1(PAI-1)、可溶性白细胞分化抗原40配体(sCD40L)、可溶性细胞间黏附因子-1(sICAM-1)及血脂的变化。结果:治疗前,两组FIB、AT-Ⅲ、t-PA、PAI-1水平比较,差异无统计学意义(P>0.05);治疗后,两组FIB、PAI-1水平下降,AT-Ⅲ、t-PA水平升高,治疗组FIB、PAI-1水平低于对照组,AT-Ⅲ、t-PA水平高于对照组,差异有统计学意义(P<0.05)。治疗前,两组sCD40L、sICAM-1水平比较,差异无统计学意义(P>0.05);治疗后,两组sCD40L、sICAM-1水平均显著下降,治疗组sCD40L、sICAM-1水平低于对照组,差异有统计学意义(P<0.05)。治疗前,两组总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)水平比较,差异无统计学意义(P>0.05);治疗后,两组TC、TG、LDL-C水平均显著下降,HDL-C升高,治疗组TC、TG、LDL-C水平低于对照组,HDL-C水平高于对照组,差异有统计学意义(P<0.05)。结论:在标准化内科治疗基础上加用补肾通脉方能够改善急性ST段抬高型心肌梗死患者PCI术后高凝状态,调节患者体内凝血-纤溶系统平衡,控制炎症反应,降低血脂水平。

头孢哌酮钠舒巴坦钠致凝血功能异常的危险因素分析

目的 探讨头孢哌酮钠舒巴坦钠致凝血功能异常的危险因素分析。方法 收集经第三代头孢菌素抗生素(头孢哌酮钠舒巴坦钠)治疗的100例患者为研究对象。根据患者是否出现凝血功能异常分为异常组(n=29)和正常组(n=71)。比较2组性别、年龄、体温、脉搏、治疗疗程、白细胞计数(white cell count,WBC)、白蛋白、尿素氮、总胆红素(total bilirubin,TBIL)、降钙素原(procalcitonin,PCT)、C反应蛋白(C-reactive protein,CRP)、饮食情况、用药剂量、合并基础病等;通过多因素Logistic回归分析明确患者凝血功能异常的危险因素;通过Person系数分析WBC、白蛋白、尿素氮、CRP与凝血酶原时间(prothrombin time,PT)、活化部分凝血酶原时间(activated partial prothrombin time,APTT)的相关性。结果 2组性别、年龄、体温、脉搏、治疗疗程、TBIL、PCT、CRP、合并高血压、合并糖尿病比较差异无统计学意义(P>0.05);异常组白蛋白水平显著低于正常组,WBC、尿素氮、CRP水平、饮食<1 200 mL/d、用药剂量≥3 g/d占比均高于正常组(P<0.05);经ROC分析证实WBC、白蛋白、尿素氮、CPR水平均可用于头孢哌酮钠舒巴坦钠在抗感染过程中凝血功能异常的预测,曲线下面积分别为0.913、0.829、0.920、0.847(P<0.05);经多因素Logistic回归分析证实,饮食<1 200 mL/d、用药剂量≥3 g/d、WBC>11.385×10~9/L、白蛋白<28.815 g/L、尿素氮>14.199μmol/L、CRP>17.629 mg/L是凝血功能异常的危险因素(P<0.05);相关性分析显示,WBC、尿素氮、CPR水平与PT、APTT均呈正相关,白蛋白与PT、APTT呈负相关(P<0.05)。结论 头孢哌酮钠舒巴坦钠在抗感染过程中致凝血功能异常受到诸多因素影响,如较高的WBC、尿素氮、CPR水平,较低的白蛋白水平,较高的用药剂量,较少的饮食等,WBC、尿素氮、CPR水平越高及白蛋白水平越低,患者凝血功能越差。

养血散寒通脉方治疗血虚寒凝型子宫内膜异位症的临床研究

【目的】观察养血散寒通脉方(由当归四逆加吴茱萸生姜汤加减而成)治疗血虚寒凝型子宫内膜异位症(EMS)的临床疗效。【方法】将120例血虚寒凝型EMS患者随机分为研究组和对照组,每组各60例。研究组给予养血散寒通脉方治疗,对照组给予少腹逐瘀颗粒治疗,疗程为3个月,并于疗程结束后随访1年。观察2组患者治疗前后各种疼痛评分[包括经期腹痛视觉模拟量表(VAS)评分和痛经、非经期盆腔痛、性交痛、盆腔压痛、骶韧带结节触痛分级评分]、卵巢子宫内膜异位囊肿大小及血清糖类抗原125(CA125)、血管内皮生长因子(VEGF)、可溶性细胞间黏附分子1(SICAM-1)、基质金属蛋白酶9(MMP-9)、组织金属蛋白酶抑制因子2(TIMP-2)水平的变化情况,并观察2组患者的临床疗效、安全性、复发情况及妊娠情况。【结果】(1)研究过程中,研究组脱落3例,对照组脱落5例,最终共112例患者纳入统计分析,其中研究组57例,对照组55例。(2)治疗3个月后,研究组的总有效率为92.98%(53/57),对照组为85.45%(47/55),组间比较,研究组的疗效明显优于对照组(P<0.05)。(3)治疗后,2组患者的各种疼痛评分(包括经期腹痛VAS评分和痛经、非经期盆腔痛、性交痛、盆腔压痛、骶韧带结节触痛分级评分)均较治疗前明显下降(P<0.05),且研究组的下降幅度均明显优于对照组(P<0.05)。(4)治疗后,2组患者的卵巢子宫内膜异位囊肿均略有缩小,但组内治疗前后及治疗后组间比较,差异均无统计学意义(P>0.05)。(5)治疗后,2组患者血清CA125、VEGF、SICAM-1、MMP-9水平均较治疗前下降(P<0.05),血清TIMP-2水平均较治疗前升高(P<0.05),且研究组对血清CA125、VEGF、SICAM-1、MMP-9水平的下降幅度及对血清TIMP-2水平的升高幅度均明显优于对照组(P<0.05)。(6)随访1年,研究组的复发率为30.19%(16/53),明显低于对照组的68.09%(32/47),组间比较,差异有统计学意义(P<0.05)。研究组21例有生育要求,其中14例妊娠,妊娠率为66.67%(14/21);对照组20例有生育要求,其中4例妊娠,妊娠率为20.00%(4/20);组间比较,研究组的妊娠率明显高于对照组,差异有统计学意义(P<0.05)。(7)治疗期间,2组患者均无明显不良反应发生,且患者的血、尿、大便常规及心电图、肝肾功能等安全性指标均无异常变化。【结论】养血散寒通脉方治疗血虚寒凝型EMS患者疗效确切,能够显著缓解患者各种疼痛症状,改善妊娠结局,有效调节血清CA125、VEGF、SICAM-1、MMP-9、TIMP-2水平。

我国脑血栓患者家系凝血因子Ⅸ基因SNP9的检测

目的 探讨凝血因子 基因在第六外显子 2 3384- 2 3387bp存在单核苷酸多态性 (SNP9)在我国北方人群脑血栓发病机制中的作用。方法 应用聚合酶链反应 -限制性片断长度多态性 (PCR- RFL P)的方法 ,检测 2 0例脑血栓患者和他们家系及 6 0例正常健康对照组凝血因子 第六外显子 2 3384- 2 3387bp多态性分布。结果 2 0例脑血栓患者和 40例他们的家系成员 ,在 Mn II酶切后 ,可见 30 7bp片断基因类型全部是 A。正常 6 0例健康对照组基因多态性基因型也显示为 A,而在阳性对照可见 A、G和 AG。结论 在这一等位基因位点脑血栓家系和正常人群基因多态性基因型均为 A型。这一位点基因对我国脑血栓患者的作用机制有待于进一步探讨。

人凝血酶原复合物中凝血因子Ⅸ效价检测中影响因素的探讨

目的探讨人凝血酶原复合物(PCC)中凝血因子Ⅸ效价检测的影响因素,优化检测条件。方法研究不同的Ca2+浓度对一期法检测凝血因子Ⅸ效价的影响,并分别考察磷酸三丁酯、聚山梨酯-80(S/D)以及硫酸鱼精蛋白中和肝素对检测的影响。结果 Ca2+浓度为0.012 5 mol/L时,检测结果最稳定,标准曲线的相关性(r2)为0.999±0.001,回收率为(99.2±1.789)%,5次重复试验的变异系数为1.80%;S/D对PCC样品中凝血因子Ⅸ效价检测的影响无统计学意义(P>0.1);PCC样品的肝素未中和时,稀释倍数的影响较大,中和后凝血因子Ⅸ效价受稀释倍数影响较小。结论优化了凝血因子Ⅸ效价检测的影响因素,最优Ca2+离子浓度为0.012 5 mol/L;S/D试剂无影响;硫酸鱼精蛋白中和肝素后,凝血因子Ⅸ效价受稀释倍数影响较小。

小鼠胚胎干细胞凝血因子Ⅸ基因的定向敲除

目的：将小鼠胚胎干细胞中凝血因子Ⅸ（ｍＦⅨ）基因定向敲除，为建立血友病Ｂ的转基因小鼠模型奠定基础；摸索建立ＥＳ细胞基因打靶技术体系。方法：将线性化的针对小鼠ｍＦⅨ基因组的基因打靶置换型载体（ｐＭＦⅨＤＥＬ）ＤＮＡ用电穿孔法转入小鼠ＥＳ细胞，经过Ｇ４１８和ＧＡＮＣ分组药物选择，用ＰＣＲ和基因组Ｓｏｕｔｈｅｒｎ杂交两种方法，鉴定药物抗性细胞中发生同源重组的情况。结果：（１）从药物抗性细胞克隆中鉴定获得了４个发生了按所设计的方式进行了同源重组的ＥＳ细胞克隆；（２）观察到在ＥＳ细胞中，ｐＭＦⅨＤＥＬ载体ＤＮＡ与内源ｍＦⅨ基因发生同源重组的频率平均为１．６７×１０－６。结论：得到了４个ｍＦⅨ基因已被敲除的ＥＳ细胞克隆；建立了ＥＳ细胞基因打靶的技术体系。

罕见凝血因子缺乏症患者围术期输血策略——附1例凝血因子Ⅺ缺乏症伴膝关节血管瘤的病例报告及文献复习

目的通过对1例凝血因子Ⅺ缺乏症伴膝关节血管瘤患者的围术期凝血管理,探讨遗传性凝血因子缺乏症患者围术期的输血策略。方法采用凝血因子活性检查和基因检测,确诊患者为凝血因子Ⅺ缺乏症,通过围术期出血风险评估,血栓弹力图以及凝血指标检测来适时监测患者的凝血状态。术前输注新鲜冰冻血浆(FFP)400 mL,术后d1输注FFP 400 mL,此后3 d每日再输注200 mL。结果患者APTT术前为97.1 s,术后为36.9 s,术中无明显出血,术后伤口愈合情况良好。结论在缺乏凝血因子制剂的情况下,凝血因子缺乏症患者在围术期可以通过积极输注FFP等血液制品来显著改善患者的凝血功能,降低术中出血的风险。